Hormone-Refractory Prostate Cancer Completed Phase 1 / 2 Trials for Sacituzumab govitecan (DB12893)

Also known as: Hormone Refractory Prostate Cancer Disease / Hormone Refractory Prostate Cancer / Castration-resistant prostate cancer / Hormone refractory prostate cancer (disorder)

IndicationStatusPhase
DBCOND0030169 (Hormone-Refractory Prostate Cancer)Completed1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01631552Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial CancerTreatment